Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA:688796)
China
· Delayed Price · Currency is CNY 77.00
-0.50 (-0.65%)
At close: Mar 9, 2026
SHA:688796 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Net Income | - | 33.54 | -382.95 | -601.95 | -545.58 | Upgrade
|
| Depreciation & Amortization | - | 165.98 | 179.3 | 174.1 | 128.1 | Upgrade
|
| Other Amortization | - | 3.2 | 3.15 | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -0.01 | -1.83 | 0.08 | -0.39 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | 0.36 | -0.15 | -44.7 | -2.13 | Upgrade
|
| Loss (Gain) on Equity Investments | - | 29.75 | 10.03 | 14.77 | 0.4 | Upgrade
|
| Stock-Based Compensation | - | 22.64 | 30.98 | 15.31 | 27.75 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 9.4 | 4.28 | 1.42 | 3.12 | Upgrade
|
| Other Operating Activities | - | 77.78 | 89.8 | 42.04 | 33.13 | Upgrade
|
| Change in Accounts Receivable | - | -96.68 | -39.02 | -4.59 | -35.86 | Upgrade
|
| Change in Inventory | - | -12.93 | 3.79 | -6.4 | -29.96 | Upgrade
|
| Change in Accounts Payable | - | -47.35 | 11.9 | 47.35 | 19.04 | Upgrade
|
| Change in Unearned Revenue | - | 30.8 | 9.98 | -8.07 | 16.75 | Upgrade
|
| Change in Income Taxes | - | - | - | -0.8 | - | Upgrade
|
| Change in Other Net Operating Assets | - | -5.24 | 4.1 | 68.17 | 19.86 | Upgrade
|
| Operating Cash Flow | - | 211.25 | -76.65 | -303.27 | -365.78 | Upgrade
|
| Capital Expenditures | - | -37.13 | -126.62 | -240.27 | -198.67 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 1.11 | 26.34 | 1.64 | 4.76 | Upgrade
|
| Divestitures | - | - | - | -6.86 | - | Upgrade
|
| Investment in Securities | - | -101.09 | - | 91.76 | 109.78 | Upgrade
|
| Investing Cash Flow | - | -137.12 | -100.28 | -153.74 | -84.13 | Upgrade
|
| Long-Term Debt Issued | - | 239.33 | 319.91 | 209.6 | - | Upgrade
|
| Long-Term Debt Repaid | - | -207.38 | -172.98 | -68.77 | -57.13 | Upgrade
|
| Net Debt Issued (Repaid) | - | 31.94 | 146.93 | 140.83 | -57.13 | Upgrade
|
| Issuance of Common Stock | - | - | - | 521.06 | 311.04 | Upgrade
|
| Repurchase of Common Stock | - | -9.51 | -8.2 | -18.99 | - | Upgrade
|
| Other Financing Activities | - | -114.46 | -176.55 | -55.69 | -34.47 | Upgrade
|
| Financing Cash Flow | - | -92.03 | -37.82 | 587.2 | 219.44 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 2.75 | 3.47 | 14.24 | -0.38 | Upgrade
|
| Net Cash Flow | - | -15.15 | -211.28 | 144.44 | -230.85 | Upgrade
|
| Free Cash Flow | - | 174.12 | -203.26 | -543.54 | -564.45 | Upgrade
|
| Free Cash Flow Margin | - | 17.76% | -28.35% | -101.81% | -159.20% | Upgrade
|
| Free Cash Flow Per Share | - | 0.44 | -0.51 | -1.43 | -1.56 | Upgrade
|
| Cash Interest Paid | - | 31.28 | 24.08 | 17 | 7.66 | Upgrade
|
| Cash Income Tax Paid | - | 9.32 | 0.64 | - | - | Upgrade
|
| Levered Free Cash Flow | - | 9.32 | -231.5 | -423.55 | -397.16 | Upgrade
|
| Unlevered Free Cash Flow | - | 66.62 | -169.1 | -388.46 | -372.52 | Upgrade
|
| Change in Working Capital | - | -131.39 | -9.24 | 95.65 | -10.18 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.